BNGO - Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities

• Bionano Genomics ( NASDAQ: BNGO ) said the U.S. Patent and Trademark Office issued a patent related to methods claiming the use of certain nanochannel arrays to detect and quantitate genetic abnormalities.
• The U.S. patent No.11,359,244 titled Characterization of Molecules in Nanofluidics, claims methods for analyzing small nucleic acid fragments in nanochannel arrays, which Bionano has used to analyze ultra-high molecular weight (UHMW) DNA for the identification of structural variants (SVs) as part of its Saphyr system, the company said in a June 29 press release.
• Bionano added the methods claim the use of certain nanochannel arrays to detect and quantitate genetic abnormalities, including a DNA translocation, amplification, inversion, and sex chromosome aneuploidy, among other things.
• The company said it believes that the methods in the patent may one day support the commercialization of assays directed to non-invasive prenatal testing (NIPT) in maternal fetal medicine or ctDNA in oncology.
• BNGO +2.11% to $1.45 premarket June 29

For further details see: